Dr. Miriam Heinig

  • March 2023 – Doctorate (Dr. rer. nat.), University of Bremen
  • since March 2018 – Doctoral researcher at the Leibniz Institute for Prevention Research and Epidemiology - BIPS GmbH
  • 2015-2018 – M.Sc. Epidemiology, University of Bremen
  • 2012-2015 – B.Sc. Health Sciences, HAW Hamburg

  • Cancer epidemiology
  • Cancer screening and early detection
  • Breast cancer
  • Postmenopausal hormone therapy
  • Secondary data

    ORCID logo

    Selected BIPS-Publications

  • Articles with peer review

  • Braitmaier M, Kollhorst B, Heinig M, Langner I, Czwikla J, Heinze F, Buschmann L, Minnerup H, García-Albéniz X, Hense H-W, Karch A, Zeeb H, Haug U, Didelez V. Effectiveness of mammography screening on breast cancer mortality - A study protocol for emulation of target trials using German health claims data. Clinical Epidemiology. 2022;14:1293-1303.
    https://doi.org/10.2147/CLEP.S376107
  • Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery - An analysis of German claims data. BMC Cancer. 2022;22:130.
    https://doi.org/10.1186/s12885-022-09240-w
  • Heinig M, Braitmaier M, Haug U. Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. Pharmacoepidemiology and Drug Safety. 2021;30(4):462-471.
    https://doi.org/10.1002/pds.5186
  • Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
    https://doi.org/10.1016/j.canep.2020.101812
    https://repository.publisso.de/resource/frl:6425860
  • Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. Future Oncology. 2021;17(18):2305-2313.
    https://doi.org/10.2217/fon-2020-1052
    https://repository.publisso.de/resource/frl:6428548
  • Posters at scientific meetings/conferences

  • Garcia de Albeniz X, Riera Guardia N, Gutierrez L, Bahmanyar S, Blin P, Droz-Perroteau C, Heinig M, Linder M, Moore N, Schulze-Rath R, Sultana J, Trifirò G, Zhang W, Zong J. Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):4008)
  • Heinig M, Haug U. The potential of claims data for long-term follow-up of breast cancer patients in Germany. 34. Deutscher Krebskongress, 19.-22. Februar 2020, Berlin.
  • Heinig M, Haug U. Changes in prescribing of hormone replacement therapy in Germany between 2004 and 2016. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):3771)

For further publications please follow this link:

The responsibility for the content of this page lies with Miriam Heinig.

Contact

Phone:
+49 (0)421 218-56-881